Does gonadotropin-releasing hormone agonist therapy affect bone mineral density in congenital adrenal hyperplasia: A Longitudinal study

被引：0
|
作者：
Flokas, Myrto [1 ,2 ]
Kollender, Sarah [3 ]
Parker, Megan [3 ]
Mallappa, Ashwini [3 ]
Merke, Deborah [3 ,4 ]
机构：
[1] Childrens Natl Hosp, Washington, DC USA
[2] NICHD, Washington, DC USA
[3] NIH, Ctr Clin, Bethesda, MD 20892 USA
[4] NICHD, Bethesda, MD USA
来源：
HORMONE RESEARCH IN PAEDIATRICS | 2022年 / 95卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5052
引用
收藏
页码：24 / 25
页数：2
相关论文
共 50 条
  • [1] Gonadotropin-Releasing Hormone Agonist Therapy and Longitudinal Bone Mineral Density in Congenital Adrenal Hyperplasia
    Flokas, Myrto Eleni
    Wakim, Paul
    Kollender, Sarah
    Sinaii, Ninet
    Merke, Deborah P.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (02): : 498 - 504
  • [2] Gonadotropin-Releasing Hormone Agonists and Bone Density in Congenital Adrenal Hyperplasia: A Call for Further Research
    Bakhtiani, Priyanka
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (06): : e1458 - e1459
  • [3] Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy
    Ripps, BA
    VanGilder, K
    Minhas, B
    Welford, M
    Mamish, Z
    JOURNAL OF REPRODUCTIVE MEDICINE, 2003, 48 (10) : 761 - 766
  • [4] Prediction of the change in bone mineral density induced by gonadotropin-releasing hormone agonist treatment for endometriosis
    Matsuo, H
    FERTILITY AND STERILITY, 2004, 81 (01) : 149 - 153
  • [5] INTERVAL BONE-MINERAL DENSITY WITH LONG-TERM GONADOTROPIN-RELEASING HORMONE AGONIST SUPPRESSION
    DAMEWOOD, MD
    SCHLAFF, WD
    HESLA, JS
    ROCK, JA
    FERTILITY AND STERILITY, 1989, 52 (04) : 596 - 599
  • [6] Changes in bone mineral density during initial and long-term gonadotropin-releasing hormone agonist therapy for prostate cancer
    McGovern, K
    Fallon, MA
    Goode, M
    Smith, M
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (09) : 1587 - 1588
  • [7] EFFECTS OF GONADOTROPIN-RELEASING HORMONE AGONIST ON UTERINE FIBROIDS AND BONE-DENSITY
    BIANCHI, G
    COSTANTINI, S
    ANSERINI, P
    ROVETTA, G
    MONTEFORTE, P
    MENADA, MV
    FAGA, L
    DECECCO, L
    MATURITAS, 1989, 11 (03) : 179 - 185
  • [8] Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia
    Quintos, JBQ
    Vogiatzi, MG
    Harbison, MD
    New, MI
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (04): : 1511 - 1517
  • [9] Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls
    Arani, Kobra Shiasi
    Heidari, Fatemeh
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2015, 13 (03)
  • [10] Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration
    Taga, M
    Minaguchi, H
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1996, 75 (02) : 162 - 165
12345